Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 308140 | 20.71 |
09:34 ET | 256710 | 20.1532 |
09:36 ET | 365417 | 20.0101 |
09:38 ET | 130031 | 20.36 |
09:39 ET | 115746 | 20.3901 |
09:41 ET | 98043 | 20.7155 |
09:43 ET | 92151 | 20.95 |
09:45 ET | 110348 | 21.1 |
09:48 ET | 65030 | 20.89 |
09:50 ET | 47787 | 21.23 |
09:52 ET | 74549 | 20.8801 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 16.8B | -90.8x | --- |
Vaxcyte Inc | 14.8B | -24.4x | --- |
Insmed Inc | 12.5B | -13.5x | --- |
Ascendis Pharma A/S | 8.9B | -15.2x | --- |
Revolution Medicines Inc | 7.3B | -12.2x | --- |
Viking Therapeutics Inc | 6.9B | -65.8x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.8B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 735.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.23 |
Book Value | $0.11 |
P/E Ratio | -90.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.